Chimeric hemagglutinin vaccine elicits broadly protective CD4 and CD8 T cell responses against multiple influenza strains and subtypes

Proceedings of the National Academy of Sciences of the United States of America
Hsin-Yu LiaoChi-Huey Wong

Abstract

Vaccination has been used to control the spread of seasonal flu; however, the virus continues to evolve and escape from host immune response through mutation and increasing glycosylation. Efforts have been directed toward development of a universal vaccine with broadly protective activity against multiple influenza strains and subtypes. Here we report the design and evaluation of various chimeric vaccines based on the most common avian influenza H5 and human influenza H1 sequences. Of these constructs, the chimeric HA (cHA) vaccine with consensus H5 as globular head and consensus H1 as stem was shown to elicit broadly protective CD4+ and CD8+ T cell responses. Interestingly, the monoglycosylated cHA (cHAmg) vaccine with GlcNAc on each glycosite induced more stem-specific antibodies, with higher antibody-dependent cellular cytotoxicity (ADCC), and better neutralizing and stronger cross-protection activities against H1, H3, H5, and H7 strains and subtypes. Moreover, the cHAmg vaccine combined with a glycolipid adjuvant designed for class switch further enhanced the vaccine efficacy with more IFN-γ, IL-4, and CD8+ memory T cells produced.

References

Dec 4, 2003·Science·Richard J Webby, Robert G Webster
May 28, 2004·Virus Research·W FiersW Min Jou
May 6, 2005·The New England Journal of Medicine·Michael T Osterholm
Jul 5, 2006·International Reviews of Immunology·Dominick J Laddy, David B Weiner
Jun 28, 2007·Expert Opinion on Investigational Drugs·Amar Safdar, Manon M J Cox
Feb 24, 2009·Nature Structural & Molecular Biology·Jianhua SuiWayne A Marasco
Feb 16, 2011·Proceedings of the National Academy of Sciences of the United States of America·Ming-Wei ChenChi-Huey Wong
Jan 29, 2013·Proceedings of the National Academy of Sciences of the United States of America·Yen-Lin HuangChi-Huey Wong
Jul 5, 2013·Clinical Microbiology Reviews·Sook-San Wong, Richard J Webby
Jan 29, 2014·Proceedings of the National Academy of Sciences of the United States of America·Juine-Ruey ChenChi-Huey Wong
May 20, 2015·Trends in Immunology·Falk NimmerjahnAnja Lux
Aug 25, 2015·Nature Medicine·Hadi M YassineBarney S Graham
Aug 26, 2015·Science·Antonietta ImpagliazzoKatarina Radošević
Jan 6, 2016·The Journal of Clinical Investigation·David J DiLilloJeffrey V Ravetch
Jan 27, 2018·Virology Journal·Giuseppe A SauttoTed M Ross
Mar 6, 2018·The Journal of Infectious Diseases·Emily J ErbeldingAnthony S Fauci
Jan 9, 2019·The Journal of Immunology : Official Journal of the American Association of Immunologists·Leonardo D Estrada, Stacey Schultz-Cherry

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.